Lexicon Pharmaceuticals LXRX Proceeds From Issuance Of Convertible Preferred Stock
Proceeds From Issuance Of Convertible Preferred Stock at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's proceeds from issuance of convertible preferred stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's proceeds from issuance of convertible preferred stock?
- Lexicon Pharmaceuticals (LXRX) reported proceeds from issuance of convertible preferred stock of $26.55M in Q1 2026.
- What does proceeds from issuance of convertible preferred stock mean?
- Captures cash inflows from the sale of preferred equity securities that carry the right to be converted into common stock. This is often used as a strategic financing tool to balance debt and equity characteristics.